img.header.ovacis.jpg

INNOVATIONS / OVACIS®

ovacis logo R.png

OVACIS® IS A GLOBALLY PATENTED INTRA-OPERATIVE DEVICE THAT ACCURATELY DISCRIMINATES BENIGN FROM MALIGNANT EPITHELIAL OVARIAN CYSTS IN 5 MINUTES. 

AS MANY AS 1 IN 10 WOMEN IS LIKELY TO HAVE AN OVARIAN CYST IN HER LIFETIME. 

An ovarian cyst happens when fluid accumulates within a thin membrane inside the ovary. Ovarian cysts are frequently found incidentally in asymptomatic women, and may sometimes be found in the course of evaluating women for pelvic pain.

Studies show that between 8% and 18% of both premenopausal and postmenopausal women have ovarian cysts, with post-menopausal cysts persisting for years.1

 

Ovarian masses or cysts are very common and 10% of women have an operation during their life for investigation of an ovarian mass. The overall incidence of a symptomatic ovarian cyst in a premenopausal female being malignant is approximately 1 in 1000, increasing to 3 in 1000 at the age of 50 years.2

BENEFITS OF OVACIS® TECHNOLOGY

01

ADVANTAGES OVER FROZEN SECTION

Diagnosis for ovarian cancer has routinely been performed via frozen section, which is subject to technical error, leading to misdiagnosis. In comparison, OvaCis® relies on cyst fluid which is homogenous, resulting in higher accuracy. 

02

VALUE IN BORDERLINE CASES

Studies have shown that with frozen section, borderline tumours have been found to have the lowest sensitivity of 31.2%, of the mucinous category, compared to OvaCis®, which accurately discriminates between benign & malignant ovarian cysts.

03

COST EFFICIENT AND CONVENIENT TO USE

OvaCis® is ideal for medical settings with no on-site facilities for histology, and costs less than frozen section. It does not require trained pathologists, substantially reduces operating theatre time, and frees up resources in the laboratory.

04

BETTER PATIENT PROGNOSIS

OvaCis® reduces operating theatre time and the patient’s surgical exposure in the operating theatre. It is the first of its kind Point-Of-Care device that returns a result in about 5 minutes, improving patient’s prognosis during surgery.

Source:
1. Subbian et al. in a study involving 135 cases of ovarian tumors found an overall accuracy of 84.2 %. They found the lowest sensitivity for borderline tumors (31.2 %) especially of the mucinous category.

2. "Ovarian Cysts".Ross & Fortin, 2016, http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/womens-health/ovarian-cysts/

3. Yeoh, Melissa. "Investigation and management of an ovarian mass." Australian family physician 44.1/2 (2015): 48.